← Back to Clinical Trials
Recruiting NCT06286800

NCT06286800 Personalized Transcranial Direct Current Stimulation in Stroke Recovery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06286800
Status Recruiting
Phase
Sponsor The Methodist Hospital Research Institute
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-12-18
Primary Completion 2027-03-14

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Transcranial direct current stimulation (tDCS) with OTSham tDCS with OT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2024-12-18 with a primary completion date of 2027-03-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The central objective of this application is to explore the neural substrate of personalized tDCS (ptDCS) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement through increased connectivity as measured by a biomarker of plasticity.

Eligibility Criteria

Inclusion Criteria: * Symptomatic ischemic or hemorrhagic stroke verified by computerized axial tomography or magnetic resonance imaging resulting in hemiparesis (MRC 1-4). * Age more than 18, Male or Female, All racial and ethnic groups * Entry into the study \>3 months post onset * Modified Ashworth Scale Score \<3 in the involved upper extremity * Passive range of motion within functional ranges at the shoulder, elbow, wrist and hand * Able to follow 2 step commands Exclusion Criteria: * Patients with history of severe alcohol or drug abuse, psychiatric illnesses like severe depression, poor motivational capacity, or severe language disturbances, particularly of receptive nature or with serious cognitive deficits (defined as unable to follow study instructions). * Patients with bilateral paresis, or weakness or sensory damage due to peripheral causes (e.g. peripheral nerve injury, muscle or orthopedic injury etc.) * Patients with severe uncontrolled medical problems (e.g. cardiovascular disease, severe rheumatoid arthritis, active joint deformity of arthritic origin, active cancer or renal disease, any kind of end-stage pulmonary or cardiovascular disease, or a deteriorated condition due to age,epilepsy or others). * Patients with unstable cardiac arrhythmia. * Pregnancy * Patients with metallic implants in the head, patients with pacemakers, patients with craniotomies, including burr holes who cannot be safely stimulated * Patients with seizures * Non-English speaking individuals will only be eligible if they can provide the appropriate translator for all the sessions of the study as no funding is available to pay for such services.

Contact & Investigator

Central Contact

Neha Sudarshan, MD

✉ nsudarshan@houstonmethodist.org

📞 9082277275

Principal Investigator

Timea Hodics, MD

PRINCIPAL INVESTIGATOR

The Methodist Hospital Research Institute

Frequently Asked Questions

Who can join the NCT06286800 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06286800 currently recruiting?

Yes, NCT06286800 is actively recruiting participants. Contact the research team at nsudarshan@houstonmethodist.org for enrollment information.

Where is the NCT06286800 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT06286800 clinical trial?

NCT06286800 is sponsored by The Methodist Hospital Research Institute. The principal investigator is Timea Hodics, MD at The Methodist Hospital Research Institute. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology